J Bone Miner Res. 2015 Oct;30(10):1747-53. doi: 10.1002/jbmr.2531. A position paper of the National Bone Health Alliance recently recommended that diagnostic criteria for osteoporosis be redefined. We review the merits and demerits of this proposal … Leer más
A986S polymorphism of CaSR is an independent predictor of PTH level in normocalcemic hyperparathyroidism patients, but not in asymptomatic hyperparathyroidism.
J Bone Miner Res. 2015 Oct 24. doi: 10.1002/jbmr.2734. [Epub ahead of print] TBS is a significant predictor of fracture risk independently of FRAX. The findings support the use of TBS as a potential adjustment … Leer más
Bone. 2015 Oct 20;83:35-47. doi: 10.1016/j.bone.2015.10.008. [Epub ahead of print] CONCLUSIONS: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is … Leer más
DM worsens bone alterations of aged mice, related to decreased bone turnover and bone vasculature and increased senescence, independently of the anti-oxidative stress machinery.
The application of the NOGG and NOF guidelines led to a decrease in BMD indications, reducing costs and improving efficiency in the diagnostic management of osteoporosis, although variability exists between the guidelines.
Osteoporos Int. 2015 Oct 28. [Epub ahead of print] Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without … Leer más
In conclusion, we found that the pharmacological management of osteoporosis in women of 50 and over in this population combines an important overuse and, to a lesser extent, underuse, although the level of inappropriateness varied … Leer más
We identified a low-frequency non-coding variant near a novel locus, EN1, with an effect size fourfold larger than the mean of previously reported common variants for lumbar spine BMD (rs11692564) which was also associated with … Leer más
Sclerostin and estradiol levels are associated with the response to bisphosphonate therapy in women with postmenopausal osteoporosis.
